Dan Gladney has been CEO since April 2019. He has 22 years of experience leading medical device companies. He was most recently CEO of ReShape Lifesciences, a company with a portfolio of devices for treating obesity and related disorders. Before that, he was Director and CEO of Lanx, Inc., a medical device company focused on spinal surgery, which was acquired by Biomet, Inc. in 2013. Prior to Lanx, Mr. Gladney was a Healthcare Operating Partner at Norwest Equity Partners (NEP), where he was responsible for strategic planning, business growth and corporate governance for NEP portfolio companies and evaluating and executing new investment opportunities for the firm. Prior to joining NEP, Mr. Gladney served as President and CEO of several successful medical device companies, including Heart Leaflet Technologies (acquired by The Bracco Group for $84M) and ACIST Medical Systems (acquired by The Bracco Group, amount undisclosed). He also served as Chairman, CEO and President of Compex Technologies, a publicly traded orthopedic and health and wellness electrotherapy company. He holds a BA from Eastern Michigan University.